Moderna, Inc. has announced that five abstracts related to its investigational mRNA therapeutics will be presented at the upcoming 2025 International Congress of Inborn Errors of Metabolism (ICIEM). The congress will take place from September 2-6, 2025, at the Kyoto International Conference Center in Kyoto, Japan. This marks a significant opportunity for the company to share insights on its ongoing research in rare metabolic disorders.
The presentations comprise three oral sessions and two poster sessions focused on Moderna’s programs addressing propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a). Notably, this event will be the first occasion on which Moderna shares data specific to MMA and GSD1a at a scientific congress.
In propionic acidemia, the presentation will highlight advances in mRNA technology that may pave the way for innovative treatment strategies. The focus on methylmalonic acidemia will provide insights into the therapeutic potential of Moderna’s mRNA platform. Additionally, the data on Glycogen Storage Disease Type 1a will showcase the company’s commitment to addressing complex genetic disorders through groundbreaking research.
Moderna’s involvement in ICIEM underscores its dedication to developing transformative treatments for patients with inborn errors of metabolism. The company continues to leverage its expertise in mRNA technology, which gained prominence during the global response to the COVID-19 pandemic, to explore new avenues in treating rare diseases.
The abstracts accepted for presentation exemplify the rigorous research and development process that Moderna undertakes in its mission to improve patient outcomes. As the field of mRNA therapeutics expands, the data shared at ICIEM will provide valuable insights into the future of treatment for these challenging conditions.
With the congress attracting global experts in the field, Moderna’s presentations are slated to spark meaningful discussions about the evolving landscape of metabolic disease therapies. The company’s participation in such an esteemed event reflects its commitment to innovation and collaboration within the scientific community.
As the date approaches, stakeholders in the healthcare and biotechnology sectors will be keenly watching the developments from this important congress, anticipating the potential impact of Moderna’s findings on future therapeutic strategies for inborn errors of metabolism.
